Eupraxia Pharmaceuticals Inc. (EPRX) vs X4 Pharmaceuticals, Inc. (XFOR)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and X4 Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.81HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
XFOR
X4 Pharmaceuticals, Inc.
$2.76HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — EPRX vs XFOR
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)XFOR -93.4% (-74.4%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
EPRX XFOR
EPRX vs XFOR: by the numbers
- •EPRX is the larger company ($261M vs $261M market cap).
- •Both run net losses; EPRX's is the smaller (0.00% vs -568.80% net margin).
Metrics side by side
Valuation
| Metric | EPRX | XFOR |
|---|---|---|
| P/S ratio | N/A | 16.44 |
| P/B ratio | 2.57 | 1.68 |
Profitability
| Metric | EPRX | XFOR |
|---|---|---|
| Gross margin | 0.00% | 81.22% |
| Operating margin | 0.00% | -247.44% |
| Net margin | 0.00% | -568.80% |
| ROE | -38.33% | -57.98% |
| ROIC | -43.56% | -37.61% |
Growth (annualized)
| Metric | EPRX | XFOR |
|---|---|---|
| Total return CAGR (5Y) | N/A | -55.06% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.